We also constructed a two-gene signature, METTL3 and METTL14, serving as an independent prognostic indicator for distinguishing ccRCC patients with different prognosis both in training, validation and our own clinical datasets. This evidence concerns the gene METTL3 and nonpapillary renal cell carcinoma.